Novo Holdings A/S, an international life sciences investor, has announced that its portfolio company, Invetx, will be acquired by Dechra Pharmaceuticals PLC, an international veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free, debt-free basis. Invetx creates novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. With its best-in-class, fully integrated discovery development and commercial manufacturing platform, Invetx leverages biotechnologies validated for human health to create...